Details of the Drug

General Information of Drug (ID: DMGB5RE)

Drug Name

Tranylcypromine

Synonyms

GJZ; Jatrosom; Parnate; Parnitene; Tranilcipromina; Transamine; Tranylcyprominum; Allphar Brand of Tranylcypromine Sulfate; Esparma Brand of Tranylcypromine Sulfate; GlaxoSmithKline Brand of Tranylcypromine Sulfate; Goldshield Brand of Tranylcypromine Sulfate; Link Brand of Tranylcypromine Sulfate; Racemic Tranylcypromine; SmithKline Brand of Tranylcypromine Sulfate; SKF 385; Trans 2 Phenylcyclopropylamine; D-Tranylcypromine; Dl-Tranylcypromine; Jatrosom (TN); L-Tranylcypromine; Parmodalin (TN); Parnate (TN); Parstelin (TN); SKF Trans-385; Sicoton (TN); Sulfate, Tranylcypromine; Tranilcipromina [INN-Spanish]; Transamine (TN); Transapin (TN); Tranylcypromine (INN); Tranylcypromine [INN:BAN]; Tranylcyprominum [INN-Latin]; Tylciprine (TN); Trans-2-Phenylcyclopropylamine; Trans-DL-2-Phenylcyclopropylamine; Trans-(-)-2-Phenylcyclopropanamine; Cyclopropanamine, 2-phenyl-, (1R-trans)-(9CI); (+)-(R)-Tranylcypromine; (+)-Tranylcypromine; (+)-trans-2-Phenylcyclopropylamine; (-)-Tranylcypromine; (1R)-2-phenylcyclopropan-1-amine; (1R,2R)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropan-1-amine; (1R,2S)-2-phenylcyclopropanamine; (1S)-2-phenylcyclopropan-1-amine; (1S,2R)-2-phenylcyclopropan-1-amine; (1S,2S)-2-phenylcyclopropan-1-amine; (2S)-2-phenylcyclopropan-1-amine; 2-Phenylcyclopropanamine; 2-phenylcyclopropan-1-amine

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Approved	[1]
Prostate cancer	2C82.0	Patented	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

133.19

Logarithm of the Partition Coefficient (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 - 3.2 hours [4]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.44 micromolar/kg/day [5]
Vd: The volume of distribution (Vd) of drug is 1.1-5.7 L/kg []
Water Solubility: The ability of drug to dissolve in water is measured as 48 mg/mL [3]

Chemical Identifiers

Formula: C9H11N
IUPAC Name: (1R,2S)-2-phenylcyclopropan-1-amine
Canonical SMILES: C1[C@H]([C@@H]1N)C2=CC=CC=C2
InChI: InChI=1S/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1
InChIKey: AELCINSCMGFISI-DTWKUNHWSA-N

Cross-matching ID

PubChem CID: 19493
ChEBI ID: CHEBI:94631
CAS Number: 3721-26-4
DrugBank ID: DB00752
TTD ID: D0H0HJ
ACDINA ID: D00697

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Monoamine oxidase (MAO)	TT32XQJ	NOUNIPROTAC	Inhibitor	[2]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[6]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[8]
Cytochrome P450 2A6 (CYP2A6)	OT52TWG3	CP2A6_HUMAN	Gene/Protein Processing	[9]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Gene/Protein Processing	[10]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[11]
Cytochrome P450 2E1 (CYP2E1)	OTHQ17JG	CP2E1_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 2J2 (CYP2J2)	OTJBTEH8	CP2J2_HUMAN	Gene/Protein Processing	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Major depressive disorder

ICD Disease Classification

6A70.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Monoamine oxidase type B (MAO-B)	DTT	MAOB	2.65E-02	1.12E-02	0.07
Monoamine oxidase type A (MAO-A)	DTT	MAOA	8.14E-01	0.05	0.1

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tranylcypromine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Tranylcypromine and Sertraline.	Depression [6A70-6A7Z]	[14]
Cyclobenzaprine	DM1YBRM	Major	Additive serotonergic effects by the combination of Tranylcypromine and Cyclobenzaprine.	Depression [6A70-6A7Z]	[15]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Tranylcypromine and Vilazodone.	Depression [6A70-6A7Z]	[16]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Tranylcypromine and Nefazodone.	Depression [6A70-6A7Z]	[16]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Tranylcypromine and Vortioxetine.	Depression [6A70-6A7Z]	[14]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Tranylcypromine and Isocarboxazid.	Depression [6A70-6A7Z]	[17]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Tranylcypromine and Milnacipran.	Depression [6A70-6A7Z]	[16]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Tranylcypromine and Escitalopram.	Depression [6A70-6A7Z]	[14]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Tranylcypromine and Desvenlafaxine.	Depression [6A70-6A7Z]	[16]
Phenelzine	DMHIDUE	Major	Additive hypertensive effects by the combination of Tranylcypromine and Phenelzine.	Depression [6A70-6A7Z]	[17]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Tranylcypromine and Clomipramine.	Depression [6A70-6A7Z]	[15]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Tranylcypromine and Doxepin.	Depression [6A70-6A7Z]	[15]
Maprotiline	DMPWB7T	Major	Additive serotonergic effects by the combination of Tranylcypromine and Maprotiline.	Depression [6A70-6A7Z]	[15]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Tranylcypromine and Esketamine.	Depression [6A70-6A7Z]	[18]
-----------


⏷ Show the Full List of 14 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Tranylcypromine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Tranylcypromine and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[15]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Repaglinide.	Acute diabete complication [5A2Y]	[19]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Glibenclamide.	Acute diabete complication [5A2Y]	[19]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Tolazamide.	Acute diabete complication [5A2Y]	[20]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-glulisine.	Acute diabete complication [5A2Y]	[19]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-aspart.	Acute diabete complication [5A2Y]	[21]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Glipizide.	Acute diabete complication [5A2Y]	[19]
Mepyramine	DMB4SFH	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Phenyltoloxamine	DMKAEQW	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[22]
Isosorbide dinitrate	DMBI4JG	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Isosorbide dinitrate.	Anal fissure/fistula [DB50]	[23]
Trimethaphan	DMHF4IQ	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Trimethaphan.	Aneurysm/dissection [BD50]	[24]
Bepridil	DM0RKS4	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Bepridil.	Angina pectoris [BA40]	[24]
Amyl nitrite	DMJKO05	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Amyl nitrite.	Angina pectoris [BA40]	[23]
Nifedipine	DMSVOZT	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Nifedipine.	Angina pectoris [BA40]	[23]
Levalbuterol	DM5YBO1	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Levalbuterol.	Asthma [CA23]	[25]
Terbutaline	DMD4381	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Terbutaline.	Asthma [CA23]	[26]
Pirbuterol	DMI5678	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Pirbuterol.	Asthma [CA23]	[25]
Ephedrine	DMMV0KW	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Ephedrine.	Asthma [CA23]	[23]
Salbutamol	DMN9CWF	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Salbutamol.	Asthma [CA23]	[25]
Formoterol	DMSOURV	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Formoterol.	Asthma [CA23]	[26]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[23]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Tranylcypromine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[15]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Droxidopa.	Autonomic nervous system disorder [8D87]	[27]
Pseudoephedrine	DMIVJ0D	Major	Additive hypertensive effects by the combination of Tranylcypromine and Pseudoephedrine.	Breathing abnormality [MD11]	[23]
Olodaterol	DM62B78	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Vilanterol	DMF5EK1	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Salmeterol	DMIEU69	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Indacaterol	DMQJHR7	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Tranylcypromine and Levomilnacipran.	Chronic pain [MG30]	[16]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Olopatadine.	Conjunctiva disorder [9A60]	[28]
Cocaine	DMSOX7I	Major	Additive hypertensive effects by the combination of Tranylcypromine and Cocaine.	Corneal disease [9A76-9A78]	[29]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Ethanol.	Cystitis [GC00]	[28]
Cyclandelate	DMO0R76	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Cyclandelate.	Dementia [6D80-6D8Z]	[24]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Tranylcypromine and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[30]
LEVONORDEFRIN	DMWDJ0H	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and LEVONORDEFRIN.	Discovery agent [N.A.]	[31]
Tetrabenazine	DMYWQ0O	Major	Additive hypertensive effects by the combination of Tranylcypromine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[32]
Deutetrabenazine	DMUPFLI	Major	Additive hypertensive effects by the combination of Tranylcypromine and Deutetrabenazine.	Dystonic disorder [8A02]	[32]
Oxcarbazepine	DM5PU6O	Major	Additive serotonergic effects by the combination of Tranylcypromine and Oxcarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[15]
Diphenhydramine	DMKQTBA	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[22]
Ethacrynic acid	DM60QMR	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Ethacrynic acid.	Essential hypertension [BA00]	[24]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Phenoxybenzamine.	Essential hypertension [BA00]	[23]
Guanethidine	DM9NSWT	Moderate	Antagonize the effect of Tranylcypromine when combined with Guanethidine.	Essential hypertension [BA00]	[33]
Mephentermine	DMFJH5Q	Major	Additive hypertensive effects by the combination of Tranylcypromine and Mephentermine.	Essential hypertension [BA00]	[34]
Oxymetazoline	DM8ZXT6	Moderate	Decreased metabolism of Tranylcypromine caused by Oxymetazoline mediated inhibition of non-CYP450 enzyme.	Eyelid inflammatory disorder [9A02]	[35]
Solifenacin	DMG592Q	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Solifenacin.	Functional bladder disorder [GC50]	[36]
Propantheline	DM2EN6G	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Propantheline.	Gastric ulcer [DA60]	[36]
Dobutamine	DMD1B8Z	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Dobutamine.	Heart failure [BD10-BD1Z]	[23]
Nesiritide	DMFOIA8	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Nesiritide.	Heart failure [BD10-BD1Z]	[23]
Chlorothiazide	DMLHESP	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Chlorothiazide.	Heart failure [BD10-BD1Z]	[23]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Bumetanide.	Heart failure [BD10-BD1Z]	[23]
Hydroflumethiazide	DMVPUQI	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[24]
Tetrahydrozoline	DMT57WC	Moderate	Decreased metabolism of Tranylcypromine caused by Tetrahydrozoline mediated inhibition of non-CYP450 enzyme.	Herpes simplex infection [1F00]	[35]
Procarbazine	DMIK367	Major	Additive hypertensive effects by the combination of Tranylcypromine and Procarbazine.	Hodgkin lymphoma [2B30]	[17]
Maraviroc	DMTL94F	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Isosorbide mononitrate	DMYLMU0	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Isosorbide mononitrate.	Hydrocephalus [8D64]	[23]
Aliskiren	DM1BV7W	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Aliskiren.	Hypertension [BA00-BA04]	[23]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Captopril.	Hypertension [BA00-BA04]	[23]
Methyldopa	DM5I621	Major	Decreased metabolism of Tranylcypromine caused by Methyldopa mediated inhibition of non-CYP450 enzyme.	Hypertension [BA00-BA04]	[33]
Levamlodipine	DM92S6N	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Levamlodipine.	Hypertension [BA00-BA04]	[23]
TAK-491	DMCF6SX	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and TAK-491.	Hypertension [BA00-BA04]	[23]
Fenoldopam	DMFAOKP	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Fenoldopam.	Hypertension [BA00-BA04]	[23]
Indapamide	DMGN1PW	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Indapamide.	Hypertension [BA00-BA04]	[23]
Trichlormethiazide	DMHAQCO	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Trichlormethiazide.	Hypertension [BA00-BA04]	[24]
Diazoxide	DML1538	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Diazoxide.	Hypertension [BA00-BA04]	[23]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Perindopril.	Hypertension [BA00-BA04]	[23]
Felodipine	DMOSW35	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Felodipine.	Hypertension [BA00-BA04]	[23]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Quinapril.	Hypertension [BA00-BA04]	[23]
Deserpidine	DMRH7CV	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Deserpidine.	Hypertension [BA00-BA04]	[37]
Telmisartan	DMS3GX2	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Telmisartan.	Hypertension [BA00-BA04]	[23]
Irbesartan	DMTP1DC	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Irbesartan.	Hypertension [BA00-BA04]	[23]
Hydrochlorothiazide	DMUSZHD	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[23]
Clevidipine butyrate	DMW4M97	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Clevidipine butyrate.	Hypertension [BA00-BA04]	[23]
Belladonna	DM2RBWK	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[36]
Propiomazine	DMKY8V1	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Propiomazine.	Insomnia [7A00-7A0Z]	[31]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Tranylcypromine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[38]
Dicyclomine	DMZSDGX	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Dicyclomine.	Irritable bowel syndrome [DD91]	[36]
Naphazoline	DMJFZDL	Moderate	Decreased metabolism of Tranylcypromine caused by Naphazoline mediated inhibition of non-CYP450 enzyme.	Itching [1F28-1G07]	[35]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[39]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Tranylcypromine and Almogran.	Migraine [8A80]	[40]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Tranylcypromine and Frovatriptan.	Migraine [8A80]	[40]
Rizatriptan	DMDJMA3	Major	Decreased metabolism of Tranylcypromine caused by Rizatriptan mediated inhibition of non-CYP450 enzyme.	Migraine [8A80]	[40]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Tranylcypromine and Naratriptan.	Migraine [8A80]	[40]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Tranylcypromine and Lasmiditan.	Migraine [8A80]	[16]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Flibanserin.	Mood disorder [6A60-6E23]	[41]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Thalidomide.	Multiple myeloma [2A83]	[28]
Ozanimod	DMT6AM2	Major	Decreased metabolism of Tranylcypromine caused by Ozanimod mediated inhibition of non-CYP450 enzyme.	Multiple sclerosis [8A40]	[42]
Dextroamphetamine	DMMIHVP	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Dextroamphetamine.	Narcolepsy [7A20]	[23]
Phenindamine	DMDTC7R	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Phenindamine.	Nasopharyngitis [CA00]	[22]
Dimenhydrinate	DM264B3	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Dimenhydrinate.	Nausea/vomiting [MD90]	[36]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Promethazine.	Nausea/vomiting [MD90]	[23]
Cyclizine	DM9G7BS	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Cyclizine.	Nausea/vomiting [MD90]	[22]
Metoclopramide	DMFA5MY	Moderate	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Metoclopramide.	Nausea/vomiting [MD90]	[43]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Tranylcypromine and Granisetron.	Nausea/vomiting [MD90]	[22]
Dolasetron	DMMG26Z	Major	Additive serotonergic effects by the combination of Tranylcypromine and Dolasetron.	Nausea/vomiting [MD90]	[22]
Ondansetron	DMOTQ1I	Major	Additive serotonergic effects by the combination of Tranylcypromine and Ondansetron.	Nausea/vomiting [MD90]	[22]
Bupropion	DM5PCS7	Major	Additive hypertensive effects by the combination of Tranylcypromine and Bupropion.	Nicotine use disorder [6C4A]	[44]
Phendimetrazine	DM6TS1N	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Phendimetrazine.	Obesity [5B80-5B81]	[23]
Amfepramone	DM9YSNQ	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Amfepramone.	Obesity [5B80-5B81]	[23]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Tranylcypromine and Sibutramine.	Obesity [5B80-5B81]	[30]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Tranylcypromine and Lorcaserin.	Obesity [5B80-5B81]	[45]
Benzphetamine	DMIJATC	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Benzphetamine.	Obesity [5B80-5B81]	[23]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Tranylcypromine and Dexfenfluramine.	Obesity [5B80-5B81]	[30]
Propylhexedrine	DMTBW2O	Moderate	Decreased metabolism of Tranylcypromine caused by Propylhexedrine mediated inhibition of non-CYP450 enzyme.	Obesity [5B80-5B81]	[35]
Polythiazide	DMCH80F	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Polythiazide.	Oedema [MG29]	[24]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Lofexidine.	Opioid use disorder [6C43]	[23]
Apraclonidine	DMO4PVE	Major	Additive hypertensive effects by the combination of Tranylcypromine and Apraclonidine.	Optic nerve disorder [9C40]	[44]
Methamphetamine	DMPM4SK	Major	Additive hypertensive effects by the combination of Tranylcypromine and Methamphetamine.	Pain [MG30-MG3Z]	[46]
Biperiden	DME78OA	Minor	Additive anticholinergic effects by the combination of Tranylcypromine and Biperiden.	Parkinsonism [8A00]	[47]
Levodopa	DMN3E57	Major	Additive hypertensive effects by the combination of Tranylcypromine and Levodopa.	Parkinsonism [8A00]	[23]
Dopamine	DMPGUCF	Major	Increased risk of hyperpyrexia by the combination of Tranylcypromine and Dopamine.	Parkinsonism [8A00]	[23]
Ritodrine	DM4V6RL	Moderate	Additive hypertensive effects by the combination of Tranylcypromine and Ritodrine.	Preterm labour/delivery [JB00]	[25]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Terazosin.	Prostate hyperplasia [GA90]	[23]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Silodosin.	Prostate hyperplasia [GA90]	[23]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[31]
Selexipag	DMAHSU0	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Selexipag.	Pulmonary hypertension [BB01]	[23]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Tolazoline.	Pulmonary hypertension [BB01]	[24]
Epoprostenol	DMUTYR2	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Epoprostenol.	Pulmonary hypertension [BB01]	[23]
Iloprost	DMVPZBE	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Iloprost.	Pulmonary hypertension [BB01]	[23]
Mesoridazine	DM2ZGAN	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Mesoridazine.	Schizophrenia [6A20]	[31]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Trifluoperazine.	Schizophrenia [6A20]	[23]
Fentanyl	DM8WAHT	Major	Additive serotonergic effects by the combination of Tranylcypromine and Fentanyl.	Sensation disturbance [MB40]	[48]
Avanafil	DM75CXN	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Avanafil.	Sexual dysfunction [HA00-HA01]	[23]
Tadalafil	DMJZHT1	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Tadalafil.	Sexual dysfunction [HA00-HA01]	[23]
Vardenafil	DMTBGW8	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[23]
Papaverine	DMCA9QP	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Papaverine.	Tonus and reflex abnormality [MB47]	[23]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[20]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[19]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Tranylcypromine and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[19]
Chlorpheniramine	DM5URA2	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[22]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Tranylcypromine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[31]
Trimeprazine	DMEMV9D	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[31]
Brompheniramine	DMFOVSD	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[22]
Xylometazoline	DMKV32D	Moderate	Decreased metabolism of Tranylcypromine caused by Xylometazoline mediated inhibition of non-CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[35]
Acrivastine	DMTIGA0	Moderate	Additive CNS depression effects by the combination of Tranylcypromine and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[22]
-----------


⏷ Show the Full List of 134 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Citric acid monohydrate	E00271	22230	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Gelatin	E00630	Not Available	Other agent
Hypromellose	E00634	Not Available	Coating agent
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 22 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tranylcypromine 10 mg tablet	10 mg	Oral Tablet	Oral
Tranylcypromine Sulfate 10mg tablet	10mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
7	Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
8	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
9	Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
10	Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system. Toxicol In Vitro. 2013 Sep;27(6):2005-12.
11	Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol. 2004 Aug 23;497(2):223-31.
12	Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004 Jun;32(6):647-60.
13	In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica. 2003 Jun;33(6):615-23.
14	Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
15	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
16	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
17	Bazire SR "Sudden death associated with switching monoamine oxidase inhibitors." Drug Intell Clin Pharm 20 (1986): 954-6. [PMID: 3816543]
18	Cerner Multum, Inc. "Australian Product Information.".
19	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
20	Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
21	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
22	Canadian Pharmacists Association.
23	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
24	Product Information. Marplan (isocarboxazid) Roche Laboratories, Nutley, NJ.
25	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
26	Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
27	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
28	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
29	Product Information. Cocaine Hydrochloride Nasal (cocaine nasal). Genus Lifesciences Inc., Allentown, PA.
30	Graber MA, Hoehns TB, Perry PJ "Sertraline-phenelzine drug interaction: a serotonin syndrome reaction." Ann Pharmacother 28 (1994): 732-5. [PMID: 7919561]
31	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
32	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
33	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
34	Davies B, Bannister R, Sever P "Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards." Lancet 1 (1978): 172-5. [PMID: 74603]
35	Cusson JR, Goldenberg E, Larochelle P "Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans." J Clin Pharmacol 31 (1991): 462-7. [PMID: 2050833]
36	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
37	Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7. [PMID: 5655478]
38	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
39	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
40	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
41	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
42	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
43	Filibeck DJ, Grimm D, Forman WB, Leidner BA "Metoclopramide-induced hypertensive crisis." Clin Pharm 3 (1984): 548-9. [PMID: 6541544]
44	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
45	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
46	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
47	Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
48	Browne B, Linter S "Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment." Br J Psychiatry 151 (1987): 210-2. [PMID: 2891392]